The FDA would probably not be happy with Cytodyn releasing any of their comments pre-approval. It's not something done by any pharmas because it could potentially prejudice the process and because the FDA's comments could refer to information that a company considers proprietary. And the last thing Cytodyn wants is to have investors start contacting the FDA because of it.

Cytodyn's only responsibility to shareholders is to abide by the FDA's guidance and get the BLA submitted effectively.